Wanzhu Tu

Wanzhu Tu

Auto-generated profile, based on publicly available information

Wanzhu Tu

Department of Biostatistics & Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Hypertension
Verified
Journal Article
Closed access
PDF file
WTWanzhu Tu
Wanzhu Tu
GEGeorge J. Eckert
George J. Eckert
LDLinda DiMeglio
Linda DiMeglio
ZYZhangsheng Yu
Zhangsheng Yu
JJJeesun Jung
Jeesun Jung
JPJ. Howard Pratt
J. Howard Pratt
In children, blood pressure (BP) and risk for hypertension are proportional to degree of adiposity. Whether the relationship to BP is similar over the full range of adiposity is less clear. Subjects from a cohort study (n=1111; 50% male and 42% black) contributed 9102 semiannual BP and height/weight assessments. The mean enrollment age was 10.2 years, and mean follow-up was 4.5 years. Adiposity was expressed as body mass index percentile, which accounted for effects of age and sex. The following observations were made. The effect of relative adiposity on BP was minimal until the body mass index percentile reached 85, beginning of the overweight category, at which point the effect of adiposity on BP increased by 4-fold. Similarly intensified adiposity effects on BP were observed in children aged ≤10, 11 to 14 years, and ≥15 years. Serum levels of the adipose tissue-derived hormone, leptin, together with heart rate, showed an almost identically patterned relation to BP to that of body mass index percentile and BP, thus implicating a possible mediating role for leptin. In conclusion, there is a marked intensification of the influence of adiposity on BP when children reach the categories of overweight and obese. Among the possible pathways, leptin may be a potentially important mediator acting through the sympathetic nervous system (reflected in heart rate). The findings have relevance to interventions designed to prevent or treat adiposity-related increases in BP and to the analytic approaches used in epidemiological studies.

1 December 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
RARajiv Agarwal
Rajiv Agarwal
WTWanzhu Tu
Wanzhu Tu
AFAlfredo E Farjat
Alfredo E Farjat
YFYoussef M K Farag
Youssef M K Farag
RTRobert Toto
Robert Toto
FIFIDELIO-DKD and FIGARO-DKD Investigators
FIDELIO-DKD and FIGARO-DKD Investigators
In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces cardiovascular and kidney failure outcomes. Finerenone also lowers the urine albumin-to-creatinine ratio (UACR). Whether finerenone-induced change in UACR mediates cardiovascular and kidney failure outcomes is unknown. To quantify the proportion of kidney and cardiovascular risk reductions seen over a 4-year period mediated by a change in kidney injury, as measured by the change in log UACR between baseline and month 4. Post hoc mediation analysis using pooled data from 2 phase 3, double-blind trials of finerenone. (ClinicalTrials.gov: NCT02540993 and NCT02545049). Several clinical sites in 48 countries. 12 512 patients with CKD and T2D. Finerenone and placebo (1:1). Separate mediation analyses were done for the composite kidney (kidney failure, sustained ≥57% decrease in estimated glomerular filtration rate from baseline [approximately a doubling of serum creatinine], or kidney disease death) and cardiovascular (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) outcomes. At baseline, median UACR was 514 mg/g. A 30% or greater reduction in UACR was seen in 3338 (53.2%) patients in the finerenone group and 1684 (27.0%) patients in the placebo group. Reduction in UACR (analyzed as a continuous variable) mediated 84% and 37% of the treatment effect on the kidney and cardiovascular outcomes, respectively. When change in UACR was analyzed as a binary variable (that is, whether the guideline-recommended 30% reduction threshold was met), the proportions mediated for each outcome were 64% and 26%, respectively. The current findings are not readily extendable to other drugs. In patients with CKD and T2D, early albuminuria reduction accounted for a large proportion of the treatment effect against CKD progression and a modest proportion of the effect against cardiovascular outcomes. Bayer AG.

24 October 2012 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
HAHisham Aljadhey
Hisham Aljadhey
WTWanzhu Tu
Wanzhu Tu
RHRichard A Hansen
Richard A Hansen
SBSusan J Blalock
Susan J Blalock
DBD Craig Brater
D Craig Brater
MMMichael D Murray
Michael D Murray
Nonsteroidal anti-inflammatory drugs (NSAIDs) may disrupt control of blood pressure in hypertensive patients and increase their risk of morbidity, mortality, and the costs of care. The objective of this study was to examine the association between incident use of NSAIDs and blood pressure in patients with hypertension.

31 January 2021 in The American Statistician
Verified
Journal Article
Closed access
STSamuel Thomas
Samuel Thomas
WTWanzhu Tu
Wanzhu Tu
Hamiltonian Monte Carlo (HMC) is a powerful tool for Bayesian computation. In comparison with the traditional Metropolis-Hastings algorithm, HMC offers greater computational efficiency, especially in higher dimensional or more complex modeling situations. To most statisticians, however, the idea of HMC comes from a less familiar origin, one that is based on the theory of classical mechanics. Its implementation, either through Stan or one of its derivative programs, can appear opaque to beginners. A lack of understanding of the inner working of HMC, in our opinion, has hindered its application to a broader range of statistical problems. In this article, we review the basic concepts of HMC in a language that is more familiar to statisticians, and we describe an HMC implementation in R, one of the most frequently used statistical software environments. We also present hmclearn, an R package for learning HMC. This package contains a general-purpose HMC function for data analysis. We illustrate the use of this package in common statistical models. In doing so, we hope to promote this powerful computational tool for wider use. Example code for common statistical models is presented as supplementary material for online publication.

1 August 2012 in Vaccine
Verified
Journal Article
Closed access
TCTeresa Cummings
Teresa Cummings
GZGregory Zimet
Gregory Zimet
DBDarron Brown
Darron Brown
WTWanzhu Tu
Wanzhu Tu
ZYZiyi Yang
Ziyi Yang
MSMarcia L. Shew
Marcia L. Shew

1 December 2009 in Archives of Pediatrics & Adolescent Medicine
Verified
Journal Article
Open access
PDF file
WTWanzhu Tu
Wanzhu Tu
BBByron E. Batteiger
Byron E. Batteiger
SWSarah Wiehe
Sarah Wiehe
SOSusan Ofner
Susan Ofner
BPBarbara Van Der Pol
Barbara Van Der Pol
JFJ. Dennis Fortenberry
J. Dennis Fortenberry
Objective To determine the time between first intercourse and first sexually transmitted infection (STI) withChlamydia trachomatis,Neisseria gonorrhoeae, orTrichomonas vaginalisand time between repeated infections. Design Observational study. Setting Three adolescent medicine clinics. Participants A cohort of 386 urban young women aged 14 to 17 years at enrollment. Main Outcome Measures Age at first intercourse; organism-specific interval between first intercourse and first STI diagnosis; interval between repeated infections; and age at first STI test prior to study participation. Results Participants had first intercourse at a young age (first, second, and third quartiles were 13, 14, and 15 years of age, respectively). By age 15 years, 25% of the women acquired their first STI, most oftenC trachomatis. Median interval between first intercourse and first STI diagnosis was 2 years. Within 1 year of first intercourse, 25% had their firstC trachomatisinfection. Repeated infections were common; within 3.6, 6, and 4.8 months, 25% of the women with priorC trachomatis, N gonorrhoeae, andT vaginalisinfection were reinfected with the respective organisms. Considerable delay in STI testing was found for those who began sex at a younger age. The median interval between first sex and first test were 4.9, 3.5, 2.1, 1.8, and 1.2 years for those who had first sex at ages 10, 11, 12, 13, and 14 years, respectively. Conclusions Timely screening and treatment are important for prevention of STI sequelae. For urban adolescent women, STI screening (especially forC trachomatis) should begin within a year after first intercourse and infected individuals should be retested every 3 to 4 months.